Potency of progestogens used in hormonal therapy: Toward understanding differential actions

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 39-47

  Hapgood, J P ^a   Africander, D ^b   Louw, R ^b   Ray, R M ^a   Rohwer, J M ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Affinity; Efficacy; Potency; Progestin; Progestogen; Steroid receptor

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; ELCOMETRINE; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE; MESTRANOL PLUS NORETHISTERONE; NOMEGESTROL ACETATE; PROMEGESTONE; STEROID RECEPTOR; TRIMEGESTONE;

BIOLOGICAL ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; HORMONAL THERAPY; HORMONE ACTION; HUMAN; NONHUMAN; RECEPTOR AFFINITY; REVIEW;

AFFINITY; EFFICACY; POTENCY; PROGESTIN; PROGESTOGEN; STEROID RECEPTOR;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTINS; RECEPTORS, STEROID;

EID: 84899969015     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.08.001     Document Type: Review

References (64)

1. A. Schindler, C. Campagnoli, R. Druckmann, J. Huber, J. Pasqualini, and K. Schweppe et al. Classification and pharmacology of progestogens Maturitas 46 2003 S7 S16
2. D. Africander, N. Verhoog, and J.P. Hapgood Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception Steroids 76 2011 636 652
3. F.Z. Stanczyk, J.P. Hapgood, S. Winer, and D.R. Mishell Jr. Progestogens used in postmenopausal hormone therapy - differences in their pharmacological properties, intracellular actions, and clinical effects Endocrine Reviews 34 2013 171 208
4. Q. Zhao, J. Pang, M. Favata, and J. Trzaskos Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression International Immunopharmacology 3 2003 1803 1817
5. H. Kuhl Pharmacology of progestogens Journal für Reproduktionsmedizin und Endokrinologie 8 2011 157 177
6. R. Sitruk-Ware Pharmacological profile of progestins Maturitas 47 2004 277 283
7. N.L. Moore, T.E. Hickey, L.M. Butler, and W.D. Tilley Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins used in HRT and contraception Molecular and Cellular Endocrinology 357 2012 60 70
8. J.P. Hapgood, D. Koubovec, A. Louw, and D. Africander Not all progestins are the same: implications for usage Trends in Pharmacological Sciences 25 2004 554 557
9. P. Huang, V. Chandra, and F. Rastinejad Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics Annual Review of Physiology 72 2010 247 272
10. P. Germain, B. Staels, C. Dacquet, M. Spedding, and V. Laudet Overview of nomenclature of nuclear receptors Pharmacological Reviews 58 2006 685 704
11. A. Phillips, K. Demarest, D.W. Hahn, F. Wong, and J.L. McGuire Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins Contraception 41 1990 399 410
12. B.J. Attardi, S. Koduri, and S.A. Hild Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat Molecular and Cellular Biology 328 2010 16 21
13. J. Botella, E. Duranti, I. Duc, A.M. Cognet, R. Delansorne, and J. Paris Inhibtion by Nomegestrol acetate and other synthetic progestin on proliferation and progesterone receptor content of T47D human breast cancer cells Journal of Steroid Biochemistry and Molecular Biology 50 1994 41 47
14. 3H] nomegestrol acetate with cytosolic progesterone receptors from the rat uterus Steroids 56 1991 323 328
15. Z. Zhang, S.G. Lundeen, Y. Zhu, J.M. Carver, and R.C. Winneker In vitro characterization of trimegestone: a new potent and selective progestin Steroids 65 2000 637 643
16. C. Hurd, and V. Moudgil Characterization of R5020 and RU486 binding to progesterone receptor from calf uterus Biochemistry 27 1988 3618 3623
17. G. Pérez-Palacios, B. Chávez, F. Vilchis, N. Escobar, F. Larrea, and A.E. Pérez Interaction of medroxyprogesterone acetate with cytosol androgen receptors in the rat hypothalamus and pituitary Journal of Steroid Biochemistry 19 1983 1729 1735
18. J. Shields-Botella, I. Duc, E. Duranti, F. Puccio, P. Bonnet, and R. Delansorne et al. An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells Journal of Steroid Biochemistry and Molecular Biology 87 2003 111 122
19. Y. Cheng, and W. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochemical Pharmacology 22 1973 220 3108
20. GraphPad Prism version 5.00 for Windows, Software, GraphPad, San Diego, CA, USA, www.graphpad.com, 2007.
21. P.J. Selman, J. Wolfswinkel, and J. Mol Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog Steroids 61 1996 133 137
22. D. Koubovec, K. Ronacher, E. Stubsrud, A. Louw, and J.P. Hapgood Synthetic progestins used in HRT have different glucocorticoid agonist properties Molecular and Cellular Endocrinology 242 2005 23 32
23. D.J. Africander Comparative study of the molecular mechanism of action of the synthetic progestins Medroxyprogesterone acetate and Norethisterone acetate 2010 University of Stellensbosch South Africa (PhD Thesis)
24. J.A. Kemppainen, E. Langley, C. Wong, K. Bobseine, W.R. Kelce, and E.M. Wilson Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone Molecular Endocrinology 13 1999 440 454
25. D. Philibert, F. Bouchoux, M. Degryse, D. Lecaque, F. Petit, and M. Gaillard The pharmacological profile of a novel norpregnance progestin (trimegestone) Gynecological Endocrinology 13 1999 316 326
26. R. Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen Contraception 62 2000 29 38
27. K. Pollow, M. Juchem, W. Elger, N. Jacobi, G. Hoffmann, and V. Möbus Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins Contraception 46 1992 561 574
28. A.C. Notides, N. Lerner, and D.E. Hamilton Positive cooperativity of the estrogen receptor Proceedings of the National Academy of Sciences of the United States of America 78 1981 4926 4930
29. S. Cho, B.L. Kagan, J. Blackford Jr., D. Szapary, and S. Simons Jr. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9 Molecular Endocrinology 19 2005 290 311
30. E. Bergink, F. van Meel, E. Turpijn, and J. van der Vies Binding of progestagens to receptor proteins in MCF-7 cells Journal of Steroid Biochemistry 19 1983 1563 1570
31. U. Fuhrmann, R. Krattenmacher, E.P. Slater, and K.-H. Fritzemeier The novel progestin Drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential Contraception 54 1996 243 251
32. ®: a progestin with a unique pharmacological profile Steroids 65 2000 629 636
33. H. Kuhl Pharmacology of estrogens and progestogens: influence of different routes of administration Climacteric 8 2005 3 63
34. A. Genazzani, M. Gambacciani, T. Simoncini, R. Anniverno, A. Becorpi, and N. Biglia et al. Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome) Gynecological Endocrinology 23 2007 436 444
35. R. Winneker, D. Bitran, and Z. Zhang The preclinical biology of a new potent and selective progestin: trimegestone Steroids 68 2003 915 920
36. W. Elger, S. Beier, K. Pollow, R. Garfield, S. Qing Shi, and A. Hillisch Conception and pharmacodynamic profile of drospirenone Steroids 68 2003 891 905
37. S. Sasagawa, Y. Shimizu, H. Kami, T. Takeuchi, S. Mita, and K. Imada et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile Steroids 73 2008 222 231
38. K. Kontula, T. Paavonen, T. Luukkainen, and L. Andersson Binding of progestogens to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes Biochemical Pharmacology 32 1983 1511 1518
39. K. Ronacher, K. Hadley, C. Avenant, E. Stubsrud, S.S. Simons, and A. Louw et al. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction Molecular and Cellular Endocrinology 299 2009 219 231
40. S.S.J. Simons What goes on behind closed doors: physiological versus pharmacological steroid hormone actions Bioessays 30 2008 744 756
41. G. Milligan Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective Molecular Pharmacology 64 2003 1271 1276
42. T.J. Berrodin, S.A. Jelinsky, N. Graciani, J.A. Butera, Z. Zhang, and S. Nagpal et al. Novel progesterone receptor modulators with gene selective and context-dependent partial agonism Biochemical Pharmacology 77 2009 204 215
43. W. Chen, N. Ohara, J. Wang, Q. Xu, J. Liu, and A. Morikawa et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells Journal of Clinical Endocrinology and Metabolism 91 2006 1296 1304
44. C. Labrie, L. Cusan, M. Plante, S. Lapointe, and F. Labrie Analysis of the androgenic activity of synthetic progestins currently used for the treatment of prostate cancer Journal of Steroid Biochemistry 28 1987 379 384
45. K.M. Ong, J.A. Blackford, B.L. Kagan, S.S. Simons, and C.C. Chow A theoretical framework for gene induction and experimental comparisons Proceedings of the National Academy of Sciences of the United States of America 107 2010 7107 7112
46. C.M. Bamberger, T. Else, A. Bamberger, F.U. Beil, and H.M. Schulte Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes Journal of Clinical Endocrinology and Metabolism 84 1999 4055 4061
47. D. Koubovec, W. Vanden, L. Vermeulen, G. Haegeman, and J.P. Hapgood Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells Molecular and Cellular Endocrinology 221 2004 75 85
48. J. Kurebayashi, T. Otsuki, K. Tanaka, Y. Yamamoto, T. Moriya, and H. Sonoo Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2 Thyroid 13 2003 249 258
49. D. Africander, R. Louw, N. Verhoog, D. Noeth, and J.P. Hapgood Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract Contraception 2011
50. G. Ramakrishnan, A. Rana, C. Das, and N.C. Chandra Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue Contraception 76 2007 297 305
51. S. Mirkin, and D.F. Archer Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17[beta]-estradiol on thrombospondin-1 mRNA in Ishikawa cells Fertility and Sterility 82 2004 220
52. F.Z. Stanczyk All progestins are not created equal Steroids 68 2003 879 890
53. M.K. McPhail The assay of progestin Journal of Physiology 83 1934 145 156
54. S.G. Lundeen, Z. Zhang, Y. Zhu, J.M. Carver, and R.C. Winneker Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone Journal of Steroid Biochemistry and Molecular Biology 78 2001 137 143
55. R. Dickey, and S. Stone Progestational potency of oral contraceptives Obstetrics and Gynecology 47 1976 106 112
56. M.I. Whitehead, P.T. Townsend, J. Pryse-Davies, T.A. Ryder, and R.J.B. King Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium New England Journal of Medicine 305 1981 1599 1605
57. G. Lane, N.C. Siddle, T.A. Ryder, R.J.B. King, and M.I. Whitehead Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium British Medical Journal 287 1983 1241 1245
58. G.I.M. Swyer, and V. Little Section of endocrinology actions and uses of orally active progestational steroids Proceedings of the Royal Society of Medicine 55 1962 15 22
59. R. King, and M. Whitehead Assessment of the potency of orally administered progestins in women Fertility and Sterility 46 1986 1062 1066
60. T. Rabe, A. Kowald, J. Ortmann, and S. Rehberger-Schneider Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro Gynecological Endocrinology 14 2000 223 230
61. J. Botella, J. Paris, and B. Lahlou The cellular mechanism of the anti-androgenic action of nomegestrol acetate, a new 19 nor progestagen, on the rat prostate Acta Endocrinologica (Copenhagen) 115 1987 544 550
62. Y. Ishida, and J. Heersche Pharmacologic doses of medroxyprogesterone acetate may cause bone loss through glucocorticoid activity: an hypothesis Osteoporosis International 13 2002 601 605
63. U. Fuhrmann, E.P. Slater, and K.H. Fritzemeier Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays Contraception 51 1995 45 52
64. G.H. Deckers, W.G. Schoonen, and H.J. Kloosterboer Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals Journal of Steroid Biochemistry and Molecular Biology 74 2000 83 92